Our 12th annual analysis reveals both an expansion of historical patterns of Series A financings and the emergence of a new group of heavily committed, relatively short-term investors.

In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.

The money raised in Series A financings for biopharma, medtech, and diagnostics start-ups is down 8% from the same period last year, but the number of deals is down even more dramatically.

Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.